Marek Tomkow

Marek Tomkow

Auto-generated profile, based on publicly available information

Marek Tomkow

University of Opole

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Current Issues in Pharmacy and Medical Sciences
Verified
Journal Article
Open access
PDF file
MTMarek Tomkow
Marek Tomkow
Radosław BalwierzRadosław Balwierz
Radosław Balwierz
AMAdam Majewski
Adam Majewski
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
The Pharmaceutical Law Act of September 6, 2001 (PLA) initially granted pharmacists the authority to issue pharmaceutical prescriptions upon its enactment. However, the legislation regulating this matter changed significantly in 2015. Article 96, section 4 of the PLA defined that, in the front of a direct health threat to a patient, a pharmacist could dispense a medication classified under the availability categories Rp or Rpz. In April 2020, the imprecise term “sudden” in relation to health threats was clarified and removed. Concurrently, all active pharmacists were granted the authority to issue prescriptions, commonly known as pro auctore and pro familiae. The aim of the study was to illustrate the influence of legislative processes on the number of prescriptions issued by practicing pharmacists. To conduct the study, we employed a legal and comparative analysis of relevant legal provisions, followed by a statistical analysis of data obtained from the E-Health Center about the number of prescriptions issued. The results indicated that since the extension of pharmacists’ rights (after April 2020), the average number of pharmaceutical prescriptions issued per month was 151,082. Between May 2020, when pharmacists were granted the authority to issue pro auctore and pro familiae prescriptions, and October 2023, 1,460,385 such prescriptions were dispensed. As a result, a significant relationship between the form of the legislative norms empowering pharmacists to independently prescribe Rx status medicines and the effectiveness of these amendments as measured by the number of prescriptions issued was demonstrated.

5 July 2024 in Pediatria i Medycyna Rodzinna
Verified
Journal Article
Open access
PDF file
AJAgata Jasińska-Balwierz
Agata Jasińska-Balwierz
Radosław BalwierzRadosław Balwierz
Radosław Balwierz
PBPaweł Biernat
Paweł Biernat
NMNatalina Makieieva
Natalina Makieieva
MTMarek Tomkow
Marek Tomkow
JLJacek Lipok
Jacek Lipok
Obesity is a chronic disease and a significant public health problem. It is estimated that more than 650 million adults, 340 million adolescents, and 39 million children are obese. Obesity leads to organ complications including type 2 diabetes, hypertension and heart diseases. The management of obesity is based on nutritional therapy combined with lifestyle changes and increased physical activity. Pharmacotherapy is also crucial, and incretin analogues are a relatively new group of drugs. Glucose-independent insulinotropic peptide and glucagon-like peptide-1 are natural incretins. These short half-life hormones are degraded by the enzyme dipeptidyl peptidase-4. Glucose-independent insulinotropic peptide and glucagon-like peptide-1 receptor agonists increase blood glucose-dependent insulin secretion while inhibiting glucagon secretion and delaying gastric emptying, thus enabling the treatment of both type 2 diabetes and obesity. Glucagon-like peptide-1 also exhibits cardioprotective and neuroprotective effects. This study aimed to review the literature on the use of glucagon-like peptide-1 analogues and verify reports on the use of glucose-dependent insulinotropic polypeptide for weight reduction. An analysis of the available literature on the efficacy and safety of liraglutide, semaglutide and tirzepatide was conducted. The potential role of these drugs in weight reduction and possible adverse effects are discussed. Attention was also paid to the pharmacokinetics of the drugs and the mechanism of incretin action in the body.

2 April 2025 in Zdrowie Publiczne i Zarządzanie
Verified
Journal Article
Open access
PDF file
MTMarek Tomków
Marek Tomków
Radosław BalwierzRadosław Balwierz
Radosław Balwierz
AMAdam Majewski
Adam Majewski
Aleksandra SzopaAleksandra Szopa
Aleksandra Szopa
For over twenty years, pharmacists in Poland did not have the right to perform even simple diagnostic tests, such as measuring blood pressure or patient’s body weight. It was only during the COVID-19 pandemic that the law was changed to allow the introduction of pharmaceutical care services in pharmacies, which enabled diagnostic tests to be performed, including tests for the SARS-CoV-2 virus. As a result, pharmacies performed 89,984 tests, of which 49,345 only in February 2022. The cessation of financing for this service by the National Health Fund (NFZ) on April 1, 2022 resulted in a significant decrease in the number of tests performed. A legal and comparative analysis of legal acts in force since 2001 was carried out, along with an analysis of data obtained from the E-Health Center. It has been shown that the change in regulations both regarding the qualifications of pharmacists and the financing of tests for the SARS-CoV-2 virus increased the number of diagnostic tests performed. Therefore, increasing the rights of pharmacists to perform diagnostic tests is the right direction of changes in the health care system in Poland.